What is BPC-157?
BPC-157 is a chain of 15 amino acids based on a protective protein found in stomach juice. Researchers have studied it mostly in animals, where it's been examined for tendon, muscle, and gut-lining repair — and that preclinical caveat matters, so our articles say it plainly.
Here you'll find how BPC-157 is thought to work, what the evidence covers, dosing questions, and comparisons with TB-500. It's available only by prescription after a licensed provider reviews your request.
46 articles on this topic
-

BPC-157 News Update: September 2026
A July FDA advisory vote moved the conversation forward, but it did not change the law or establish that BPC-157 works in people. A new rat study adds evidence, with the same important limit: it was not a human trial.
-

Hims Peptides: What Hims & Hers Plans to Sell
Hims & Hers says a peptide and wellness category is coming, but the rollout is phased. Some offerings are planned for 2026, while BPC-157 depends on unfinished FDA rulemaking.
-

What Is an IND? A Plain-English FDA Guide
An IND is the filing that lets a sponsor begin testing an investigational drug in people. It opens a research path, not a sales or prescription path.
-

BPC-157 and Alcohol: Can You Drink Safely?
No published human study has tested the combination. The alcohol claims come from experiments in mice and rats, which cannot establish a safe drinking amount or a hangover remedy.
-

FDA Category 2 Bulk Drug Substances: What It Means
Category 2 means FDA has identified significant safety concerns about a nominated compounding ingredient. Here is what the category tells a patient, and why leaving it does not mean approval.
-

Gray Market Peptides: What Johns Hopkins Found
Johns Hopkins says the market for unverified peptide vials is growing much faster than the human evidence. The useful question is what a prescription and a pharmacy change.
-

BPC-157 Myths: 10 Claims Checked
Ten familiar claims about BPC-157, graded against the studies: what comes from rats, what has been observed in people, and what remains unknown.
-

BPC-157 Human Studies: What the Evidence Shows
Human evidence exists, but it is much smaller than online summaries make it sound: a few short, uncontrolled reports cannot establish that BPC-157 works or is safe long term.
-

Who Discovered BPC-157? Predrag Sikirić
Predrag Sikirić's group at the University of Zagreb described the parent gastric peptide in 1992 and the 15-amino-acid fragment BPC-157 in 1993. The history is much clearer than the human evidence.
-

KLOW Peptide Before and After: An Honest Timeline
There is no clinical before-and-after timeline for KLOW because no published study has tested the finished blend. Here is what component studies measured over three days to 12 weeks—and why those clocks are not a promise.
-

Where to Inject KLOW Peptide: Abdomen or Thigh?
KLOW is given into the fatty layer beneath the skin, usually in an abdomen or thigh area named in the pharmacy directions. The exact boundaries and rotation plan come from the prescription, not from an online diagram.
-

There Is No Best BPC-157 Brand. Ask This Instead.
No company holds an approval to make BPC-157, so the “brands” ranked online are websites, not manufacturers. What's worth comparing is the pharmacy and the prescription behind the vial.
-

BPC-157 WADA Status: Prohibited All Year Round
If you're tested in your sport, the answer is short. BPC-157 is prohibited all year round, a prescription doesn't change that, and the one exemption that could is unlikely to be granted, by USADA's own account.
-

BPC-157 Dosage by Body Weight: No Human Formula
There is no validated weight-based BPC-157 dose for people. The micrograms-per-kilogram numbers online were lifted from rat experiments, not human dose-finding trials.
-

Peptide Research 2026: What Three Reviews Found
Three review papers landed within a few weeks of each other this summer. They agree the animal work is real, the human evidence is thin, and that gap is the thing worth understanding.
-

503A Bulks List: What It Means
The 503A bulks list is a narrow ingredient pathway for patient-specific compounding. Here is how it differs from FDA categories, drug review and the separate 503B list.
-

Is BPC-157 FDA Approved? No—The Vote Was Advisory
BPC-157 is not FDA-approved, and no approved BPC-157 product exists anywhere. The July 2026 vote was advice on compounding, not drug approval.
-

Paradigm Peptides: A Lab Certificate Is Not Proof
The Paradigm Peptides sentencing exposed a simple weakness in buying medicine from an unlicensed website: a polished lab certificate can be fake. The safer difference is an accountable chain—a prescriber, a named pharmacy and records regulators can inspect.
-

How to Report Peptide Side Effects So It Counts
An NBC News investigation in August found that problems linked to peptides often go nowhere at all. Here is where a report actually lands, and in what order to make it.
-

KLOW Peptide Stack: Four Peptides in One Vial
A “stack” just means taking more than one peptide at a time. KLOW is one that comes already mixed — four peptides in a single prescribed vial, so there is nothing for you to assemble.
Page 1 of 3 · 46 articles